Patent SG-11201407649R-A (SG)
Title: Method for treating non-small cell lung cancer
Inventor: DUKSIN CHEN
IPC: A61K31/7105
Filed: 2013-05-17
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 November 2013 (21.11.2013) WIPOIPCT (10) International Publication Number WO 2013/173757 A1 (51) International Patent Classification: A61K31/7105 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/041652 17 May 2013 (17.05.2013) English English (30) Priority Data: 61/649,092 18 May 2012 (18.05.2012) US (71) Applicant (for all designated States except BB, US): TEVA PHARMACEUTICAL INDUSTRIES LTD. [IL/IL]; 5 Basel Street, P.O. Box 3190, Petach Tikva 49131 (IL). (71) Applicant (for BB only)-. TEVA PHARMACEUTICALS USA, INC. [US/US]; 1090 Horsham Road, North Wales, PA 19454 (US). (72) Inventors; and (71) Applicants (for US only): DUKSIN, Chen [IL/IL]; 5 Romema Street, Tel Aviv 69419 (IL). TESSLER, Shoshi [IL/IL]; Hanotrim 24, Zichron Ya'acov (IL). (74) Agent: WHITE, John P.; Cooper & Dunham LLP, 30 Rockefeller Plaza, New York, NY 10112 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: METHOD FOR TREATING NON-SMALL CELL LUNG CANCER Arm A Paclitaxel (200 mg/M 2 2 IV) and and Carboplatin (AUC 6) q 21 21 days plus Custirsen (640 mg IV) weekly * Continue treatment treatment until disease disease progression or Arm A Paclitaxel (200 mg/M IV) Carboplatin (AUC 6) q days plus Custirsen (640 mg IV) weekly * Continue until progression or -> P R O G R S 11 R V Arm B E V Paclitaxel (200 mg/M^ IV) and Carboplatin (AUC S A 6) q 21 days S L Continue treatment until disease progression or I Follow unacceptable toxicity 0 Follow N / Up l> i> m i> i-H cn i-H o CJ o & If removed from treatment for any reason, follow for survival (57) Abstract: The present invention provides methods for treating human a patient afflicted with unresectable, advanced or meta­ static non-small cell lung cancer comprising periodically administering to the human patient chemotherapy' comprising an amount of docetaxel; and 640mg of an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (SEQ ID NO: ), 1 wherein the anti-clusterin oligonucleotide has phosphorothioate a backbone throughout, has sugar moieties of nucleotides 1 -4 and 18-21 bearing 2'-0-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, thereby treating the human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer. The present invention also provides compositions and combinations, packages, and uses thereof for treating human patient a afflicted with unresectable, advanced or metastatic non-small cell lung cancer.